Sign in

CIK 0001570562

  • Accelerated filer

Evolus, Inc.

Sign in to watch
Ticker
EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
461385614
Phone
+1 949-284-4555
Business address
520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA, 92660
Former names
Evolus, Inc.
  1. 4 Planned sale See Remarks sold 2,252 shares at $10.85 ($24,438)
  2. 4 Planned sale Chief Financial Officer sold 1,586 shares at $10.85 ($17,211)
  3. 4 Planned sale See Remarks sold 10,502 shares at $10.85 ($113,967)
  4. 4 Open-market sale Chief Financial Officer sold 3,276 shares at $14.98 ($49,074)
  5. 4 Open-market sale Chief Marketing Officer sold 5,631 shares at $15.85 ($89,251)
  6. 4 Grant or award Director acquired 23,014 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market sale See Remarks sold 471,432 shares at an average $12.74 ($6,005,628)
  9. 4 Open-market sale Director sold 7,500 shares at $12.96 ($97,203)
  10. 4 Open-market sale Director sold 10,361 shares at an average $12.64 ($131,010)
  11. 4 Open-market sale Director sold 28,000 shares at $12.93 ($362,012)
  12. 4 Open-market sale See Remarks sold 16,051 shares at $12.72 ($204,127)
  13. 4 Open-market sale See Remarks sold 3,441 shares at $12.72 ($43,761)
  14. 4 Open-market sale Chief Financial Officer sold 2,423 shares at $12.72 ($30,814)
  15. 4 Open-market sale See Remarks sold 6,236 shares at $13.86 ($86,431)
  16. 4 Open-market sale See Remarks sold 27,603 shares at $13.92 ($384,350)
  17. 4 Open-market sale Chief Financial Officer sold 5,672 shares at $13.92 ($78,978)
  18. 4 Open-market sale See Remarks sold 96,566 shares at $13.92 ($1,344,604)
  19. 4 Planned sale See Remarks sold 7,706 shares at $13.08 ($100,804)
  20. 4 Planned sale See Remarks sold 1,821 shares at $13.08 ($23,821)

Page 3 of 13 · 252 filings